Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Open Access
- 24 August 2021
- preprint content
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
The effectiveness of BNT162b2, ChAdOx1, and mRNA-1273 vaccines against new SARS-CoV-2 infections requires continuous re-evaluation, given the increasingly dominant Delta variant. We investigated the effectiveness of the vaccines in a large community-based survey of randomly selected households across the UK. We found that the effectiveness of BNT162b2 and ChAd0x1 against any infections (new PCR positives) and infections with symptoms or high viral burden is reduced with the Delta variant. A single dose of the mRNA-1273 vaccine had similar or greater effectiveness compared to a single dose of BNT162b2 or ChAdOx1. Effectiveness of two doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity following second doses differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positives but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence that effectiveness varied by dosing interval, but protection was higher among those vaccinated following a prior infection and younger adults. With Delta, infections occurring following two vaccinations had similar peak viral burden to those in unvaccinated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden are reduced with Delta.Keywords
This publication has 33 references indexed in Scilit:
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman PrimatesPublished by Cold Spring Harbor Laboratory ,2021
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study)Published by Cold Spring Harbor Laboratory ,2021
- Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection SurveyThe Lancet Public Health, 2020
- Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparisonThe Lancet Infectious Diseases, 2020
- Immunological considerations for COVID-19 vaccine strategiesNature Reviews Immunology, 2020
- A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2Cell, 2020
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaquesNature, 2020
- Regression Modeling StrategiesPublished by Springer Science and Business Media LLC ,2015